TMCnet News
OSE Immunotherapeutics and Nantes University Hospital Announce Initiation of a Phase 1/2 Clinical Trial to Evaluate CD28 Antagonist FR104 in Patients Undergoing Renal Transplantation
NANTES, France, Dec. 03, 2020 (GLOBE NEWSWIRE) -- OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), and Nantes University Hospital (CHU de Nantes) today announced that the French National Agency for Medicines and Health Products Safety (ANSM) and the French Central Ethics Committee (CPP) approved the initiation of a Phase 1/2 trial evaluating first administration of FR104, a monoclonal antibody CD28 antagonist, in patients undergoing renal transplant. This study will be conducted as part of a collaboration agreement between OSE Immunotherapeutics and the University Hospital of Nantes. Alexis Peyroles, Chief Executive Officer of OSE Immunotherapeutics, comments: “We are very pleased to be collaborating with the University Hospital of Nantes and the ITUN, a very high-level clinical investigation center, with a team of excellence in renal graft at European level. The initiation of a first clinical trial of FR104 in renal transplantation is a key step in the product’s development. Since graft rejection is a major issue for patients that results in need for lifelong immunosuppressive treatment, the evaluation of FR104 immunotherapy in the long-term control of post-transplant immune reaction addresses a key therapeutic challenge that requires innovative solutions. OSE Immunotherapeutics is also working on a new Phase 2 clinical trial with FR104 in a niche indication in autoimmune diseases as the product has showcased a strong development potential in a number of indications.” The purpose of this Phase 1/2 clinical trial is to investigate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of FR104 in renal transplant patients. A long-term follow up assessment will be performed one year after the end of the study. Long term safety and efficacy will be evaluated in terms of renal function, incidence of rejection and all suspected FR104 related adverse events. The study will be conducted under the sponsorship of Nantes University Hospital. Pr. Gilles Blancho, Head of the ITUN (Institute of Urology and Nephrology Transplantation) within the University Hospital, will serve as the coordinating investigator. OSE Immunotherapeutics will provide its product FR104 and a financial support. Pr. Gilles Blancho, Head of the ITUN, added: “Despite continuous progress in immunosuppressive treatments, the need for medical advances for renal transplant recipients remains very strong. Through FR104, we are hoping to develop an innovative and promising immunotherapy. The key issue in organ transplant is having available efficient immunosuppressive treatments with minimal side effects, thus preserving patients’ quality of life. Moreover, the clinical collaboration between ITUN and OSE fits into Nantes hospital’s commitment to foster partnerships with the pharmaceutical industry in order to help our clinicians participate in clinical trials while simultaneously enabling our patients to benefit from the latest therapeutic advancements.” FR104 is a monoclonal antibody and an antagonist of CD28. This pegylated monovalent antibody selectively inhibits the CD28 receptor and has potential clinical applications in autoimmune diseases and transplantation. Due to its selective immunosuppressive activity directed at effector T cells, OSE plans to investigate FR104 for use in kidney transplantation. Selective CD28 blockage by FR104 might represent an effective immunomodulation strategy by reducing the activation of T lymphocytes, while sparing the activity of regulatory T lymphocytes. Several studies conducted with FR104 in preclinical models of transplant and other immune-mediated diseases have generated significant immune data demonstrating its ability to promote immunological modulation(1) and ability to reinforce immunosuppression(2). In particular, when used as a monotherapy or in combination according to the models, FR104 has shown to efficiently control graft-versus-host disease (GVHD) or renal graft rejection and this control was superior to the one observed with non-selective CD28-antagonist CTLA4-Ig(3, 4). Additionally, the results from the Phase 1 clinical (5) study of FR104 have shown a good clinical and biological safetywith an immunosuppressive activity potentially applicable to transplantation and immune-mediated diseases.
ABOUT CHU DE NANTES Nantes University Hospital (CHU Nantes), the 6th largest French university hospital, provides high-quality comprehensive health services. Among the top research institutions in France, CHU de Nantes focuses on excellence and innovation. Nantes University Hospital participates each year in about 1,300 clinical trials, involving approximately 6,500 patients, leading to over 1,200 publications in peer-reviewed journals. Over the years, CHU de Nantes has developed numerous research partnerships with SMEs and major actors of the biotech and medtech industry. We believe opening up to our ecosystem is a real game-changer for the development of innovations for the benefit of patients and health professionals. ABOUT OSE Immunotherapeutics OSE Immunotherapeutics is an integrated biotechnology company focused on developing and partnering therapies to control the immune system for immuno-oncology and autoimmune diseases. The company’s immunology research and development platform is focused on three areas: T-cell-based vaccination, Immuno-Oncology (focus on myeloid targets), Auto-immunity & Inflammation. Its balanced first-in-class clinical and preclinical portfolio has a diversified risk profile: Vaccine platform
Immuno-oncology platform
Auto-immunity and inflammation platform
For more information: https://ose-immuno.com/en/ Contacts
Forward-looking Statements |